<DOC>
<DOCNO>EP-0618920</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NOVEL PHOSPHONO-SUCCINIC ACID DERIVATIVES, PROCESS FOR PRODUCING THEM AND MEDICAMENTS CONTAINING THESE COMPOUNDS
</INVENTION-TITLE>
<CLASSIFICATIONS>C07F9572	C07F96506	C07F9553	A61K31675	C07F940	A61K3166	C07F900	A61K31662	A61K3166	C07F958	A61P300	A61P300	A61K31675	A61K31662	A61P314	C07F96509	C07F938	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>C07F	C07F	C07F	A61K	C07F	A61K	C07F	A61K	A61K	C07F	A61P	A61P	A61K	A61K	A61P	C07F	C07F	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>C07F9	C07F9	C07F9	A61K31	C07F9	A61K31	C07F9	A61K31	A61K31	C07F9	A61P3	A61P3	A61K31	A61K31	A61P3	C07F9	C07F9	</CLASSIFICATIONS-FOURTH>
<APPLICANTS>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
<APPLICANT-NAME>
BOEHRINGER MANNHEIM GMBH
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
BAUSS FRIEDER
</INVENTOR-NAME>
<INVENTOR-NAME>
BOSIES ELMAR
</INVENTOR-NAME>
<INVENTOR-NAME>
ESSWEIN ANGELIKA
</INVENTOR-NAME>
<INVENTOR-NAME>
TSAKLAKIDIS CHRISTOS
</INVENTOR-NAME>
<INVENTOR-NAME>
BAUSS, FRIEDER
</INVENTOR-NAME>
<INVENTOR-NAME>
BOSIES, ELMAR
</INVENTOR-NAME>
<INVENTOR-NAME>
ESSWEIN, ANGELIKA
</INVENTOR-NAME>
<INVENTOR-NAME>
TSAKLAKIDIS, CHRISTOS
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Phosphonosuccinic acid derivatives of the 
formula I 


 
in which R signifies a possibly substituted amino 

group of the general formula -NR
1
R
2
, whereby R
1
 and 
R
2
, independently of one another, each signify 
hydrogen, C
1
-C
6
-alkyl, C
3
-C
6
-alkenyl or C
3
-C
6
-alkynyl 
or R represents a heterocyclic ring which is 

selected from the group which contains the aziridine, 
azetidine, pyrrolidine, piperidine, azepine, 

morpholine, thiomorpholine, imidazoline, pyridine, 
pyrimidine, pyrazine and imidazole ring, which can 

possibly be substituted once or twice by C
1
-C
6
-alkyl, 
chlorine or bromine, alk signifies a valency 

bond, a methylene, a saturated or unsaturated, 
straight-chained or branch alkylene chain with 2-6 

carbon atoms and R
3
, R
4
, R
5
, in each case independently 
of one another, signify hydrogen, C
1
-C
6
-alkyl 
or benzyl, as well as their pharmacologically 

acceptable salts and enantiomers, whereby, for the 
case that R
3
 = R
4
 = R
5
 = CH
3
 and alk signifies a 
valency bond, R cannot be the dimethylamino group. 
Process for the preparation of phosphonosuccinic 
acid derivatives of the formula I 


  
 

in which R signifies a possibly substituted amino 
group of the general formula -NR
1
R
2
, whereby R
1
 and 
R
2
, independently of one another, each signify 
hydrogen, C
1
-C
6
-alkyl, C
3
-C
6
-alkenyl or C
3
-C
6
-alkynyl 
or R represents a heterocyclic ring which is 

selected from the group which contains aziridine, 
azetidine, pyrrolidine, piperidine, azepine, 

morpholine, thiomorpholine, imidazoline, pyridine, 
pyrimidine, pyrazine and imidazole ring which can 

possibly be substituted once or twice by C
1
-C
6
-alkyl, 
chlorine or bromine, alk signifies a valency 

bond, a methylene, a saturated or unsaturated, 
straight-chained or branched alkylene chain with 

2 - 6 carbon atoms and R
3
, R
4
, R
5
 , in each case 
independently of one another, signify hydrogen, 

C
1
-C
6
-alkyl or benzyl, as well as of their pharmacologically 
acceptable salts and enantiomers, 

whereby, for the case that R
3
 = R
4
 = R
5
 = CH
3
 and 
alk signifies a valency bond, R cannot be the 

dimethylamino group, characterised in that, in per 
se known manner, one 


a) reacts carboxylic acid derivatives of the general 
formula II 


 
in which R, alk and R
4
 have the above-given meanings 
and Y is a group which can be removed, such as e.g. 

Hal or O-SO
2
-Z, whereby Hal is to be chloride, 
bromide or iodide and Z methyl, phenyl, p-methyl-phenyl 

or p-nitrophenyl, with a phosphonoacetic 
acid ester of the general formula III 


  
 

in which R
3
 and R
5
 possess the above-given meaning, 
whereby, for the case that R signifies a primary or 

secondary amino group, this must be present in 
protected form, perhaps as acylamino or phthaloylimido 

group, end possibly partly or completely 
saponifies the resultant esters to the corresponding 

acids of the general formula I, or 
b) reacts compounds of the general formula IV 

 
in which R, alk, R
3
 and R
4
 have the above-given 
meanings, with a dialkyl phosphite of the general 

formula V 

H-P(O)(OR
5
)
2
 
in which R
5
 has the above-given meaning, and possibly 
partly or completely saponifies the resultant esters 

to the corresponding acids of the general formula I, 
or 
c) brings a compound of the general formula VI or 
VII 


 
in which R
3
, R
4
 and R
5
 possess the above-given 
meanings, to reaction in per se known manner with 

a compound of the general formula VIII 

R-alk-M
  
 

in which R possesses the above-given meanings and 
M signifies hydrogen or an alkali metal or alkaline 

earth metal, and possibly partly or completely 
saponifies the resultant esters to the corresponding 

acids of the general formula I and, if desired, 
converts into pharmacologically acceptable salts. 
Medicaments containing at least one compound 
according to claim 1, besides usual carrier and 

adjuvant materials. 
Use of compounds according to claim 1 for the 
production of medicaments for the treatment of 

calcium metabolism disturbances. 
</CLAIMS>
</TEXT>
</DOC>
